FOLH1 and prostate carcinoma: This might be explained by the following reasons: Firstly, PSMA is a type II transmembrane glycoprotein that is strongly overexpressed in PCa cells (both primary tumor and metastases) and low in benign prostate tissue (22–24), making 18F-PSMA-1007 PET/CT a promising technique for detecting and locating prostate cancer.